2022 In-Person CTSA Program Annual Meeting Top Ten Takeaways
At the beginning of this month, nearly 400 people gathered in person for our annual fall CTSA Program Meeting, marking the first time we were able to hold the meeting in person in three years. If you were unable to attend, the top ten takeaways from the meeting, which were presented by Mike Kurilla, M.D., Ph.D., director of the Division of Clinical Innovation at NCATS, and Laura James, M.D., director of the University of Arkansas for Medical Sciences Translational Research Institute and co-chair of the CTSA Program Steering Committee, are excerpted below. However, we encourage you to get the full story from our meeting materials and recordings.
10. Addressing best practices around career ladders, competencies to help support recruitment, retention strategies for hubs and the importance of how CTSA administrators and teams can support Diversity, Equity and Inclusion in our participant and patient-facing initiatives.
9. We must develop strategies to be more inclusive and create better dialogue with patients to develop a broad and representative patient population to ensure we have equitable research.
8. Preliminary results of the DEIA Task Force’s exploratory Phase I baseline assessment of leadership diversity across the CTSA consortium reveal that, while some evidence of perceived leadership diversity exists, there is much work to be done to develop a common set of goals and build our collective capacity to address diversity within the infrastructures of our hubs.
7. For the community, impactful research is about “Are we moving the needle on health equity?”
6. Social Determinants play a key role in the lived experiences of the communities we work with, so it's important to be intentional about understanding how policy, standard technology and organization maturity can facilitate broad enterprise-wide changes.
5. Diversity in biomedical research can be achieved through a variety of approaches.
4. Conversations focused on diversity in clinical trials, providing descriptions of successful practice models and guidance toward developing new initiatives in the industry to take back to our Hubs.
3. As part of our effort to reverse our declining life expectancy in the U.S. we need to revamp our evidence-generation system and develop effective approaches to combat misinformation.
2. 3D provides much more depth than 2D for discussions.
1. We have big aspirations for the future of clinical translational science and together we can achieve the audacious goals of getting more treatments to all people more quickly.
See all materials and recordings from the 2022 In-Person CTSA Program Annual Meeting.